Orna Therapeutics
620 Memorial Drive, 2nd Floor
Cambridge
MA
02139
United States
Tel: +1 202-930-4762
Website: http://www.ornatx.com/
18 articles with Orna Therapeutics
-
Simnova and Orna Therapeutics Collaborate to Advance Orna's Next Generation Circular RNA Technology in China
1/5/2023
Shanghai Xianbo Biotech Co., Ltd. and BiTE-armed CAR-T cell therapies, and Orna Therapeutics today announced a collaboration agreement to discover, develop, and commercialize multiple potential therapeutics in the area of oncology.
-
BioSpace checked in with some of the members of our NextGen Bio Class of 2022 to see what they've done to earn their place on the list - and what's on the horizon.
-
Orna Therapeutics Raises $221 Million Series B Financing to Advance Circular RNA Platform and Accelerate Programs to the Clinic
8/16/2022
Orna Therapeutics, a biotechnology company pioneering a new class of fully engineered circular RNA therapies, announced the initial closing of its $221 million Series B financing.
-
Merck and Orna Therapeutics Collaborate to Advance Orna’s Next Generation of RNA Technology
8/16/2022
Merck, known as MSD outside the United States and Canada, and Orna Therapeutics, a biotechnology company pioneering a new investigational class of engineered circular RNA therapies, announced a collaboration agreement to discover, develop, and commercialize multiple programs, including vaccines and therapeutics in the areas of infectious disease and oncology.
-
BioImpact Capital Announces a Multi-Billion Dollar Landmark Transaction in Vaccines and Cancer
8/16/2022
BioImpact Capital, an affiliate of MPM Capital, announced that Orna Therapeutics, a portfolio company it created, incubated, and funded, has agreed to a landmark collaboration with one of the world’s leading biopharmaceutical companies.
-
Merck and Orna will explore various therapeutic and vaccine programs in a collaboration worth a potential $3.5 billion.
-
August 1 is RNA Day. BioSpace takes a look at recent breakthroughs in RNA therapeutics, and the vast potential of the "vital biological molecule."
-
Orna announced first-ever data from its lead isCAR program that validates both the technology and its LNP delivery platform. BioSpace spoke with ORNA CEO Tom Barnes.
-
Orna Therapeutics Announces First-in-Class, Breakthrough Data Demonstrating Potential of Circular RNA Platform at ASGCT 2022
5/16/2022
Orna Therapeutics, a biotechnology company pioneering a new class of fully engineered circular RNA therapies, for the first time announces data from its lead isCAR program that validates the potential of the company's novel oRNA technology and LNP delivery platform.
-
Orna Therapeutics to Present Novel, First-in-Class Circular RNA Data at Upcoming ASGCT 2022 Annual Meeting
5/2/2022
Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA therapeutics, today announced multiple data presentations at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting.
-
BioSpace Movers & Shakers, March 11
3/11/2022
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers -
Orna Therapeutics Bolsters Leadership Team with Key Executive and Board Appointments
3/9/2022
Orna Therapeutics today announced the appointment of Thomas Ebeling to the Board of Directors and William Shen, Ph.D., as Chief Business Officer.
-
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
-
From the continuing fight against COVID-19 to new companies emerging in exciting therapeutic areas to the people who mattered most, here’s a look at just some of the biggest successes, most dramatic flops – and a few that fall somewhere in between.
-
BioSpace Movers & Shakers, Dec. 17
12/17/2021
As 2021 moves closer to its end, biopharma and life sciences companies from across the globe continue to strengthen their leadership teams and boards with these Movers & Shakers. -
Orna Therapeutics Expands Leadership Team with Key Executive Hires
12/16/2021
Robert Mabry, Ph.D. joins as Chief Scientific Officer from Takeda Pharmaceuticals and Nishla Keiser, Ph.D., J.D. appointed as Chief Legal and Strategy Officer from Intellia Therapeutics.
-
With the Thanksgiving holiday upon us, BioSpace felt it was important to give thanks for some of the positive things that have happened this year. And there are many!
-
Orna, which began as an academic query at the Massachusetts Institute of Technology (MIT), is a biotechnology company creating fully engineered circular RNA, or O-shaped RNA therapies for the treatment of cancer, autoimmune, and genetic disorders.